BE1000535A4 - Composition pharmaceutique injectable a base d'amoxicilline. - Google Patents
Composition pharmaceutique injectable a base d'amoxicilline. Download PDFInfo
- Publication number
- BE1000535A4 BE1000535A4 BE8700157A BE8700157A BE1000535A4 BE 1000535 A4 BE1000535 A4 BE 1000535A4 BE 8700157 A BE8700157 A BE 8700157A BE 8700157 A BE8700157 A BE 8700157A BE 1000535 A4 BE1000535 A4 BE 1000535A4
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- amoxicillin
- injection
- trihydrate
- pharmaceutical composition
- Prior art date
Links
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 title claims abstract description 50
- 229960003022 amoxicillin Drugs 0.000 title claims abstract description 30
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 238000002347 injection Methods 0.000 title claims abstract description 24
- 239000007924 injection Substances 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 229960004920 amoxicillin trihydrate Drugs 0.000 claims abstract description 19
- 239000000725 suspension Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 150000004684 trihydrates Chemical class 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 16
- 235000019445 benzyl alcohol Nutrition 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 159000000000 sodium salts Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 239000003589 local anesthetic agent Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000402754 Erythranthe moschata Species 0.000 description 2
- 229960002793 amoxicillin sodium Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241001137251 Corvidae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 238000011672 OFA rat Methods 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- BYHDFCISJXIVBV-YWUHCJSESA-M amoxicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=C(O)C=C1 BYHDFCISJXIVBV-YWUHCJSESA-M 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8602332A FR2594334B1 (fr) | 1986-02-20 | 1986-02-20 | Composition pharmaceutique injectable a base d'amoxicilline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1000535A4 true BE1000535A4 (fr) | 1989-01-24 |
Family
ID=9332343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE8700157A BE1000535A4 (fr) | 1986-02-20 | 1987-02-20 | Composition pharmaceutique injectable a base d'amoxicilline. |
Country Status (13)
| Country | Link |
|---|---|
| BE (1) | BE1000535A4 (es) |
| CH (1) | CH668706A5 (es) |
| DE (1) | DE3705349A1 (es) |
| EG (1) | EG18455A (es) |
| ES (1) | ES2003687A6 (es) |
| FR (1) | FR2594334B1 (es) |
| GB (1) | GB2186797B (es) |
| GR (1) | GR870278B (es) |
| IT (1) | IT1202567B (es) |
| LU (1) | LU86781A1 (es) |
| MY (1) | MY101146A (es) |
| NL (1) | NL8700416A (es) |
| ZA (1) | ZA871225B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1720533B1 (en) * | 2004-02-24 | 2015-03-25 | Sandoz Ag | Amoxicillin instant granulate |
| CN102614294B (zh) * | 2011-01-27 | 2015-02-25 | 瑞普（天津）生物药业有限公司 | 一种复方阿莫西林混悬注射剂及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3969524A (en) * | 1974-08-13 | 1976-07-13 | Hoffmann-La Roche Inc. | Stable amoxicillin dosage form |
| FR2302736A1 (fr) * | 1975-03-07 | 1976-10-01 | Beecham Group Ltd | Composition antibiotique injectable |
| US4079131A (en) * | 1975-01-02 | 1978-03-14 | American Home Products Corporation | Permanent suspension pharmaceutical dosage forms |
| EP0029668A1 (en) * | 1979-11-08 | 1981-06-03 | Beecham Group Plc | Pharmaceutical injectable composition and two-pack container for said composition |
| EP0080862A1 (en) * | 1981-12-02 | 1983-06-08 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
-
1986
- 1986-02-20 FR FR8602332A patent/FR2594334B1/fr not_active Expired - Lifetime
-
1987
- 1987-02-11 MY MYPI87000127A patent/MY101146A/en unknown
- 1987-02-19 CH CH617/87A patent/CH668706A5/fr not_active IP Right Cessation
- 1987-02-19 NL NL8700416A patent/NL8700416A/nl active Search and Examination
- 1987-02-19 GB GB8703883A patent/GB2186797B/en not_active Expired - Lifetime
- 1987-02-19 EG EG90/87A patent/EG18455A/xx active
- 1987-02-19 IT IT19426/87A patent/IT1202567B/it active
- 1987-02-19 DE DE19873705349 patent/DE3705349A1/de not_active Ceased
- 1987-02-19 ES ES8700425A patent/ES2003687A6/es not_active Expired
- 1987-02-19 LU LU86781A patent/LU86781A1/fr unknown
- 1987-02-19 ZA ZA871225A patent/ZA871225B/xx unknown
- 1987-02-20 BE BE8700157A patent/BE1000535A4/fr not_active IP Right Cessation
- 1987-02-20 GR GR870278A patent/GR870278B/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3969524A (en) * | 1974-08-13 | 1976-07-13 | Hoffmann-La Roche Inc. | Stable amoxicillin dosage form |
| US4079131A (en) * | 1975-01-02 | 1978-03-14 | American Home Products Corporation | Permanent suspension pharmaceutical dosage forms |
| FR2302736A1 (fr) * | 1975-03-07 | 1976-10-01 | Beecham Group Ltd | Composition antibiotique injectable |
| EP0029668A1 (en) * | 1979-11-08 | 1981-06-03 | Beecham Group Plc | Pharmaceutical injectable composition and two-pack container for said composition |
| EP0080862A1 (en) * | 1981-12-02 | 1983-06-08 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
Non-Patent Citations (2)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 89, no. 22, 27 novembre 1978, page 366, résumé no. 185963v, Columbus, Ohio, US; "Sterile amoxicillin trihydrate; sterile amoxicillin trihydrate for suspension", & FED. REGIST. 25-08-1978, 43(166), 38000-2 * |
| CHEMICAL ABSTRACTS, vol. 97, no. 20, 15 novembre 1982, page 370, résumé no. 168766f, Columbus, Ohio, US; UNITED STATES FOOD AND DRUG ADMINISTRATION: "Penicillin antibiotic drugs for animal use; sterile amoxicillin trihydrate for suspension", & FED. REGIST. 10-09-1982, 47(176), 39813 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2186797B (en) | 1990-01-24 |
| IT8719426A0 (it) | 1987-02-19 |
| ES2003687A6 (es) | 1988-11-01 |
| GB2186797A (en) | 1987-08-26 |
| EG18455A (en) | 1992-12-30 |
| GB8703883D0 (en) | 1987-03-25 |
| ZA871225B (en) | 1987-10-28 |
| LU86781A1 (fr) | 1987-09-15 |
| DE3705349A1 (de) | 1987-08-27 |
| CH668706A5 (fr) | 1989-01-31 |
| IT1202567B (it) | 1989-02-09 |
| FR2594334B1 (fr) | 1990-01-12 |
| MY101146A (en) | 1991-07-31 |
| FR2594334A1 (fr) | 1987-08-21 |
| NL8700416A (nl) | 1987-09-16 |
| GR870278B (en) | 1987-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0858329B1 (fr) | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation | |
| KR102659761B1 (ko) | Sglt-2 억제제를 포함하는 액상 약제학적 조성물 | |
| HU230300B1 (hu) | Prosztaglandin E1 helyi beadásra alkalmas készítmények | |
| CH667993A5 (de) | Pharmazeutische formulierungen zur behandlung von gedaechtnisstoerungen. | |
| CA2663387C (fr) | Composition a base de xanthoxyline et son utilisation en cosmetique | |
| US9114110B2 (en) | Suspension type topical formulations comprising cyclic depdipeptide | |
| AU616502B2 (en) | Treatment of inflammatory disorders in humans | |
| JP2013515020A (ja) | 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体 | |
| US11801231B2 (en) | Oral compositions and methods of use | |
| EP2200582B1 (fr) | Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant | |
| AT509777B1 (de) | Adhesive retardformulierungen zur lokalen verabreichung von curcumin | |
| US9220702B2 (en) | Composition for external use on skin for inflammatory diseases | |
| FR2609394A1 (fr) | Solution aqueuse contenant un acide quinolone carboxylique | |
| CN115702936A (zh) | 一种芦可替尼组合物及其用途 | |
| DE60103284T2 (de) | Antifungizide zusammensetzung von ketoconazole zum auftragen | |
| WO2009007660A9 (fr) | Compositions liquides ou pateuses destinees a l'apport en elements essentiels a la synthese et a la constitution des proteoglycanes, notamment pour le traitement de la degradation du cartilage | |
| FR2594334A1 (fr) | Composition pharmaceutique injectable a base d'amoxicilline | |
| JP2008510003A5 (es) | ||
| EP3197458B1 (fr) | Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines cytokines chimio-attractantes | |
| EP2938326B1 (fr) | Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation | |
| DE69815277T2 (de) | Nimelulide enthaltendes pharmazeutisches präparat zur oralen verabreichung | |
| EP0029790B1 (fr) | Nouveau médicament à base d'aspirine et d'heptaminol | |
| JP2018529752A (ja) | サンダルウッド油及び口腔粘膜炎に関連するその用途 | |
| EP4351506B1 (en) | Lipid crystalline compositions with enhanced stability for topical delivery of active agent combinations | |
| EP0635267A1 (fr) | Compositions à base d'acides gras douées de propriétés anti-inflammatoires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: *BRISTOL-MYERS CY Effective date: 20070220 |